Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase I trial to determine Givastomig in newly diagnosed (frontline treatment) gastric cancer and esophageal cancer in combination with chemotherapy and a checkpoint inhibitor

Next Previous
Trial Profile

A phase I trial to determine Givastomig in newly diagnosed (frontline treatment) gastric cancer and esophageal cancer in combination with chemotherapy and a checkpoint inhibitor

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 28 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Givastomig (Primary) ; Nivolumab (Primary) ; Capecitabine; Fluorouracil; Folinic acid; Oxaliplatin
  • Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
  • Focus Therapeutic Use
  • Sponsors I-MAB Biopharma

Most Recent Events

  • 18 Jun 2025 According to an I-Mab media release, the company announced that it will host a webinar to recap the data being presented at ESMO GI 2025, with a key opinion leader (KOL), on Tuesday, July 8, 2025 at 2:00pm EDT.
  • 03 Jun 2025 According to an I-Mab media release, the trial has been selected for a Mini Oral presentation at the ESMO GI Cancers Congress, scheduled for July 2, 2025.
  • 15 May 2025 According to an I-Mab media release, dose escalation combination data on U.S. patients will be presented at the European Society of Medical Oncology Gastrointestinal Cancers Congress 2025, being held July 2-5 in Barcelona, Spain.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top